Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. The submission qualifies for the NMPA’s “green channel” pathway, an expedited review process for innovative medical technologies addressing significant clinical needs, which is expected to streamline regulatory timelines and facilitate faster market access.
This milestone marks a key step in Ventripoint’s global expansion strategy, targeting China’s vast cardiology market. Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness and portability, but variability in interpretation and limited access to advanced modalities like MRI create demand for AI-driven tools that enhance diagnostic accuracy and workflow efficiency.
Ventripoint’s VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by Knowledge Based Reconstruction technology, the platform enables assessment of all four heart chambers with high accuracy, supporting diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China’s scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care.”
The NMPA green channel designation is reserved for devices that address unmet clinical needs or offer significant advantages over existing options. This could reduce the typical review time, which often takes years, and accelerate adoption. For Ventripoint, entry into China represents a substantial revenue opportunity, given the country’s large patient population and growing healthcare investment.
The company will provide further updates as the regulatory process progresses. For more information, visit the original release at www.newmediawire.com.
